CHST13 (carbohydrate sulfotransferase 13) is a Golgi membrane-localized enzyme that catalyzes sulfate transfer to the C4 position of N-acetylgalactosamine (GalNAc) residues in chondroitin, a major cartilage proteoglycan 1. This enzymatic activity is essential for chondroitin sulfate biosynthesis and proteoglycan maturation. CHST13 expression is upregulated during liver injury, particularly in response to endothelin receptor antagonists, where it mediates inflammatory and fibrotic responses through chondroitin sulfate production 1. In hepatocellular carcinoma (HCC), CHST13 negatively modulates metastatic potential and chemosensitivity through mitogen-activated protein kinase (MAPK) pathway activation; reduced CHST13 expression correlates with increased invasiveness and drug resistance 2. Additionally, CHST13 inhibition enhances metastatic capacity, suggesting a tumor-suppressive role 2. Clinically, CHST13 polymorphisms predict drug-induced liver toxicity from bosentan, an endothelin receptor antagonist used for pulmonary arterial hypertension 34. Genetic variants in CHST13 are associated with poor functional outcomes following ischemic stroke 5 and may contribute to hypopituitarism pathogenesis 6. CHST13 shows promise as a druggable target, with computational studies identifying capsaicin as a potential inhibitor for HCC therapy 7.